Effects of the protein tyrosine kinase inhibitor, herbimycin A, on prolactin gene expression in GH(3) and 235-1 pituitary tumor cells

被引:7
作者
Billis, WH [1 ]
White, BA [1 ]
机构
[1] UNIV CONNECTICUT, CTR HLTH, GRAD PROGRAM DEV BIOL, DEPT ANAT, FARMINGTON, CT 06030 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 1997年 / 1358卷 / 01期
关键词
herbimycin A; protein tyrosine kinase; prolactin; lactotrope; calcium; EGF; TRH; bFGF;
D O I
10.1016/S0167-4889(97)00053-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The high basal level of prolactin (PRL) gene expression in rat pituitary GH(3) cells is maintained through the spontaneous activity of voltage sensitive calcium channels (VSCCs). This can be observed experimentally by addition of 0.5 mM CaCl2 to GH(3) cells cultured in a low calcium, serum-free medium. CaCl2 specifically induces PRL gene expression and this induction is inhibited by VSCC blockers. PRL gene expression is also stimulated by several hormones and growth factors. In the present study, we examined the effects of tyrosine kinase inhibitors on the ability of CaCl2, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF) and thryrotropin-releasing hormone (TRH) to increase PRL mRNA levels. Of several PTK inhibitors used, one PTK inhibitor, herbimycin A, specifically inhibited the CaCl2-induced increase in cytoplasmic and nuclear prolactin (PRL) mRNA without affecting cell viability, cell-cell and cell-matrix adhesion, or the expression of several other genes. The effects of herbimycin A were reversible. In cells pretreated with herbimycin A, PRL mRNA levels were reduced by 69 +/- 12% (P < 0.001; n = 4). Western blot analysis using anti-phosphotyrosine antibody revealed a decrease of 91 +/- 1% (P < 0.001; n = 4) in the phosphotyrosine content of proteins in the molecular weight range of 130-160 kDa. After changing the: medium back to SFM plus 0.5 mM CaCl2, levels of PRL mRNA increased over a period of several hours, and this increase was accompanied by the tyrosine phosphorylation of two or more proteins in the approximate size range of 130-160 kDa. Herbimycin A also inhibited PRL gene expression in the independently-derived 235-1 lactotrope cell line and lowered the tyrosine specific phosphorylation of protein(s) in a similar size range. Herbimycin A inhibited the ability of bFGF, EGF and TRH to stimulate PRL gene expression in GH(3) cells. Again, in cells pretreated with herbimycin A, bFGF induced a reappearance of tyrosine-specific phosphorylation, followed by a reappearance of PRL mRNA. These findings provide evidence for a role for at least one PTK which is necessary for basal and stimulated PRL gene expression. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:31 / 38
页数:8
相关论文
共 30 条
[1]  
BANDYOPADHYAY SK, 1989, J BIOL CHEM, V264, P14216
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   FYN TYROSINE KINASE IS INVOLVED IN KERATINOCYTE DIFFERENTIATION CONTROL [J].
CALAUTTI, E ;
MISSERO, C ;
STEIN, PL ;
EZZELL, RM ;
DOTTO, GP .
GENES & DEVELOPMENT, 1995, 9 (18) :2279-2291
[4]   CALCIUM CALMODULIN REGULATION OF THE RAT PROLACTIN GENE IS CONFERRED BY THE PROXIMAL ENHANCER REGION [J].
DAVIS, JRE ;
HOGGARD, N ;
WILSON, EM ;
VIDAL, ME ;
SHEPPARD, MC .
MOLECULAR ENDOCRINOLOGY, 1991, 5 (01) :8-12
[5]   PITUITARY CALCIUM-CHANNEL MODULATION AND REGULATION OF PROLACTIN GENE-EXPRESSION [J].
DAY, RN ;
MAURER, RA .
MOLECULAR ENDOCRINOLOGY, 1990, 4 (05) :736-742
[6]   EFFECTS OF CALCIUM AND CALCIUM IONOPHORES ON PROLACTIN GENE-EXPRESSION IN GH3 AND 235-1 RAT PITUITARY-TUMOR CELLS [J].
DELIDOW, BC ;
LAILTRECKER, M ;
WHITE, BA .
MOLECULAR ENDOCRINOLOGY, 1992, 6 (08) :1268-1276
[7]  
GICK GG, 1985, J BIOL CHEM, V260, P7614
[8]   STIMULATION OF 3T3 CELLS INDUCES TRANSCRIPTION OF THE C-FOS PROTO-ONCOGENE [J].
GREENBERG, ME ;
ZIFF, EB .
NATURE, 1984, 311 (5985) :433-438
[9]   CALCIUM-CHANNEL AGONISTS AND ANTAGONISTS - EFFECTS OF CHRONIC TREATMENT ON PITUITARY PROLACTIN SYNTHESIS AND INTRACELLULAR CALCIUM [J].
HINKLE, PM ;
JACKSON, AE ;
THOMPSON, TM ;
ZAVACKI, AM ;
COPPOLA, DA ;
BANCROFT, C .
MOLECULAR ENDOCRINOLOGY, 1988, 2 (11) :1132-1138
[10]  
HONMA Y, 1989, CANCER RES, V49, P331